DS
ALXN

David Shaw’s Alexion Pharmaceuticals ALXN Stock Holding History

David Shaw’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,241,928
Closed -$228M – 5580
2021
Q2 		$228M Buy
1,241,928
+162,843
+15% +$28M 0.2% 89
2021
Q1 		$165M Buy
1,079,085
+245,535
+29% +$38M 0.16% 125
2020
Q4 		$130M Buy
833,550
+59,210
+8% +$7.61M 0.12% 201
2020
Q3 		$88.6M Buy
774,340
+457,991
+145% +$49.4M 0.09% 253
2020
Q2 		$35.5M Sell
316,349
-419,804
-57% -$44.6M 0.04% 501
2020
Q1 		$66.1M Sell
736,153
-148,056
-17% -$14.5M 0.1% 226
2019
Q4 		$95.6M Sell
884,209
-752,592
-46% -$80.5M 0.11% 213
2019
Q3 		$160M Buy
1,636,801
+1,372,387
+519% +$155M 0.2% 96
2019
Q2 		$34.6M Buy
264,414
+101,955
+63% +$13.1M 0.04% 500
2019
Q1 		$22M Sell
162,459
-692,264
-81% -$86.1M 0.03% 684
2018
Q4 		$83.2M Buy
854,723
+330,717
+63% +$39.1M 0.11% 197
2018
Q3 		$72.8M Sell
524,006
-67,885
-11% -$8.52M 0.09% 279
2018
Q2 		$73.5M Sell
591,891
-58,472
-9% -$6.83M 0.1% 258
2018
Q1 		$72.5M Buy
650,363
+299,529
+85% +$35.8M 0.1% 246
2017
Q4 		$42M Buy
350,834
+235,075
+203% +$28.6M 0.06% 408
2017
Q3 		$16.2M Sell
115,759
-173,825
-60% -$23.6M 0.03% 705
2017
Q2 		$35.2M Buy
+289,584
New +$33.7M 0.06% 396
2016
Q4 		– Sell
-41,144
Closed -$5.03M – 3676
2016
Q3 		$5.04M Sell
41,144
-150,649
-79% -$19.4M 0.01% 1294
2016
Q2 		$22.4M Sell
191,793
-7,732
-4% -$1.1M 0.04% 512
2016
Q1 		$27.8M Sell
199,525
-158,716
-44% -$23.3M 0.05% 426
2015
Q4 		$68.3M Sell
358,241
-130,228
-27% -$22.7M 0.1% 237
2015
Q3 		$76.4M Buy
488,469
+161,903
+50% +$29.5M 0.11% 215
2015
Q2 		$59M Buy
326,566
+304,907
+1,408% +$52.6M 0.09% 272
2015
Q1 		$3.75M Sell
21,659
-135,423
-86% -$24.5M 0.01% 1564
2014
Q4 		$29.1M Buy
157,082
+96,173
+158% +$17.8M 0.04% 542
2014
Q3 		$10.1M Sell
60,909
-112,945
-65% -$18.5M 0.01% 1076
2014
Q2 		$27.2M Sell
173,854
-28,684
-14% -$4.53M 0.04% 539
2014
Q1 		$30.8M Buy
+202,538
New +$32.2M 0.04% 452
2013
Q4 		– Sell
-83,653
Closed -$10M – 4779
2013
Q3 		$9.72M Sell
83,653
-43,218
-34% -$4.74M 0.02% 1038
2013
Q2 		$11.7M Buy
+126,871
New +$12.2M 0.02% 790

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

David Shaw's ALXN Position: Q3 2021 in Review

David Shaw sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,241,928 shares — an estimated $228M sold.

David Shaw first reported a position in ALXN in Q2 2013 and held it in 30 quarters. The position peaked at $228M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • David Shaw reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • David Shaw sold 1,241,928 Alexion Pharmaceuticals shares in Q3 2021, an estimated $228M.
  • David Shaw first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 30 quarters.
  • David Shaw's Alexion Pharmaceuticals position peaked at $228M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on D.E. Shaw & Co's 13F filing for Q3 2021, filed 15 Nov 2021.